BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38643891)

  • 1. CyTOF analysis revealed platelet heterogeneity in breast cancer patients received T-DM1 treatment.
    Ma J; Pang Y; Shang Y; Xie C; Xu X; Chan L; Zhang Z; Wang W
    Clin Immunol; 2024 Jun; 263():110227. PubMed ID: 38643891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
    von Minckwitz G; Huang CS; Mano MS; Loibl S; Mamounas EP; Untch M; Wolmark N; Rastogi P; Schneeweiss A; Redondo A; Fischer HH; Jacot W; Conlin AK; Arce-Salinas C; Wapnir IL; Jackisch C; DiGiovanna MP; Fasching PA; Crown JP; Wülfing P; Shao Z; Rota Caremoli E; Wu H; Lam LH; Tesarowski D; Smitt M; Douthwaite H; Singel SM; Geyer CE;
    N Engl J Med; 2019 Feb; 380(7):617-628. PubMed ID: 30516102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and responses of brain metastases during treatment with trastuzumab emtansine (T-DM1) for HER2 positive advanced breast cancer: A single institution experience.
    Okines A; Irfan T; Khabra K; Smith I; O'Brien M; Parton M; Noble J; Stanway S; Somaiah N; Ring A; Johnston S; Turner N
    Breast J; 2018 May; 24(3):253-259. PubMed ID: 28833867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
    Perez EA; de Haas SL; Eiermann W; Barrios CH; Toi M; Im YH; Conte PF; Martin M; Pienkowski T; Pivot XB; Burris HA; Stanzel S; Patre M; Ellis PA
    BMC Cancer; 2019 May; 19(1):517. PubMed ID: 31146717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. STAT3 activation confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive breast cancer.
    Wang L; Wang Q; Gao M; Fu L; Li Y; Quan H; Lou L
    Cancer Sci; 2018 Oct; 109(10):3305-3315. PubMed ID: 30076657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting Thrombocytopenia in Patients With Breast Cancer Treated With Ado-trastuzumab Emtansine.
    Modi ND; Sorich MJ; Rowland A; McKinnon RA; Koczwara B; Wiese MD; Hopkins AM
    Clin Breast Cancer; 2020 Apr; 20(2):e220-e228. PubMed ID: 31892489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exposure-response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane.
    Li C; Wang B; Chen SC; Wada R; Lu D; Wang X; Polhamus D; French J; Vadhavkar S; Strasak A; Smitt M; Joshi A; Samant M; Quartino A; Jin J; Girish S
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1079-1090. PubMed ID: 29022084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab.
    Al Rabadi LS; Cook MM; Kaempf AJ; Saraceni MM; Savin MA; Mitri ZI
    BMC Cancer; 2021 Oct; 21(1):1150. PubMed ID: 34706686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics and exposure-response of trastuzumab emtansine in advanced breast cancer previously treated with ≥2 HER2-targeted regimens.
    Chen SC; Quartino A; Polhamus D; Riggs M; French J; Wang X; Vadhavkar S; Smitt M; Hoersch S; Strasak A; Jin JY; Girish S; Li C
    Br J Clin Pharmacol; 2017 Dec; 83(12):2767-2777. PubMed ID: 28733983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety Evaluation of Trastuzumab Emtansine in Japanese Patients with HER2-Positive Advanced Breast Cancer.
    Watanabe J; Ito Y; Saeki T; Masuda N; Takano T; Takao S; Nakagami K; Tsugawa K; Nakagawa S; Kanatani K; Nakayama T
    In Vivo; 2017; 31(3):493-500. PubMed ID: 28438884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical research progress of T-DM1 in breast cancer].
    Li LX; Ma F
    Zhonghua Zhong Liu Za Zhi; 2021 Jan; 43(1):92-97. PubMed ID: 33472319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Anti-HER2 Treatments Combined With Atezolizumab on the Tumor Immune Microenvironment in Early or Metastatic Breast Cancer: Results From a Phase Ib Study.
    Hamilton EP; Kaklamani V; Falkson C; Vidal GA; Ward PJ; Patre M; Chui SY; Rotmensch J; Gupta K; Molinero L; Li Y; Emens LA
    Clin Breast Cancer; 2021 Dec; 21(6):539-551. PubMed ID: 34154926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab emtansine: mechanisms of action and drug resistance.
    Barok M; Joensuu H; Isola J
    Breast Cancer Res; 2014 Mar; 16(2):209. PubMed ID: 24887180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical benefit of treatment after trastuzumab emtansine for HER2-positive metastatic breast cancer: a real-world multi-centre cohort study in Japan (WJOG12519B).
    Yokoe T; Kurozumi S; Nozawa K; Ozaki Y; Maeda T; Yazaki S; Onishi M; Fujimoto A; Nakayama S; Tsuboguchi Y; Iwasa T; Sakai H; Ogata M; Terada M; Nishimura M; Onoe T; Masuda J; Kurikawa M; Isaka H; Hagio K; Shimomura A; Okumura Y; Futamura M; Shimokawa M; Takano T
    Breast Cancer; 2021 May; 28(3):581-591. PubMed ID: 33389616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer.
    Rinnerthaler G; Gampenrieder SP; Greil R
    Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30841523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab.
    Dzimitrowicz H; Berger M; Vargo C; Hood A; Abdelghany O; Raghavendra AS; Tripathy D; Valero V; Hatzis C; Pusztai L; Murthy R
    J Clin Oncol; 2016 Oct; 34(29):3511-3517. PubMed ID: 27298406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter?
    Fabi A; Giannarelli D; Moscetti L; Santini D; Zambelli A; Laurentiis M; Caruso M; Generali D; Valle E; Leonardi V; Cannita K; Arpino G; Filippelli G; Ferretti G; Giampaglia M; Montemurro F; Nisticò C; Gasparro S; Cognetti F
    Future Oncol; 2017 Dec; 13(30):2791-2797. PubMed ID: 29182361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
    Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA
    J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer.
    Girish S; Gupta M; Wang B; Lu D; Krop IE; Vogel CL; Burris Iii HA; LoRusso PM; Yi JH; Saad O; Tong B; Chu YW; Holden S; Joshi A
    Cancer Chemother Pharmacol; 2012 May; 69(5):1229-40. PubMed ID: 22271209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an antibody-drug conjugate (ADC) for treatment of metastatic breast cancer.
    Bender B; Leipold DD; Xu K; Shen BQ; Tibbitts J; Friberg LE
    AAPS J; 2014 Sep; 16(5):994-1008. PubMed ID: 24917179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.